Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues

Will Pfizer ($PFE) come back at AstraZeneca ($AZN)? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals. Now, sources are telling the Financial Times and CNBC that the collapse of AbbVie's ($ABBV) buyout of Ireland-based Shire ($SHPG) make another Pfizer bid unlikely. Unless the midterm elections go against President Obama, that is. Report | Report

Suggested Articles

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.